{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:04:10Z","timestamp":1767830650714,"version":"3.49.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>This therapeutic drug monitoring (TDM) grand round describes a patient with serious valproic acid intoxication. A total valproic acid level of 844 mg\/L and an unbound valproic acid level of 604 mg\/L were observed. Meropenem was administered to enhance the clearance of valproic acid. This off-label usage of meropenem is based on the drug\u2013drug interaction between carbapenems and valproic acid, which reduced the level of valproic acid within 24 hours after administration.<\/jats:p>","DOI":"10.1097\/ftd.0000000000000973","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T12:18:31Z","timestamp":1645013911000},"page":"359-362","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Meropenem to Treat Valproic Acid Intoxication"],"prefix":"10.1097","volume":"44","author":[{"given":"Elise J.","family":"Smolders","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Radboud Institute of Health Sciences, Radboud University Medical Center ; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Ter Heine","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Radboud Institute of Health Sciences, Radboud University Medical Center ; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Natsch","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Radboud Institute of Health Sciences, Radboud University Medical Center ; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kees","family":"Kramers","sequence":"additional","affiliation":[{"name":"Department of Pharmacology-Toxicology and Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1081\/CLT-120014645","article-title":"Valproic acid toxicity: overview and management","volume":"40","author":"Sztajnkrycer","year":"2002","journal-title":"J Toxicol Clin Toxicol."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1345\/aph.1P135","article-title":"L-carnitine for acute valproic acid overdose: a systematic review of published cases","volume":"44","author":"Perrott","year":"2010","journal-title":"Ann Pharmacother."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00003246-199302000-00026","article-title":"Acute valproic acid intoxication: enhanced drug clearance with oral-activated charcoal","volume":"21","author":"Farrar","year":"1993","journal-title":"Crit Care Med."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3109\/15563650.2015.1035441","article-title":"Extracorporeal treatment for valproic acid poisoning: systematic review and recommendations from the EXTRIP workgroup","volume":"53","author":"Ghannoum","year":"2015","journal-title":"Clin Toxicol (Phila)."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1177\/0091270009334377","article-title":"Valproic acid plasma concentration decreases in a dose-independent manner following administration of meropenem: a retrospective study","volume":"49","author":"Haroutiunian","year":"2009","journal-title":"J Clin Pharmacol."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/FTD.0000000000000316","article-title":"The effect of different carbapenem antibiotics (ertapenem, imipenem\/cilastatin, and meropenem) on serum valproic acid concentrations","volume":"38","author":"Wu","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/03602530701690341","article-title":"Interaction between valproic acid and carbapenem antibiotics","volume":"39","author":"Mori","year":"2007","journal-title":"Drug Metab Rev."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"2120.e5","DOI":"10.1016\/j.ajem.2019.158426","article-title":"Use of meropenem to treat valproic acid overdose","volume":"37","author":"Dreucean","year":"2019","journal-title":"Am J Emerg Med."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/jcpt.12705","article-title":"Intentional use of carbapenem antibiotics for valproic acid toxicity: a case report","volume":"43","author":"Khobrani","year":"2018","journal-title":"J Clin Pharm Ther."},{"key":"R12-20250603","first-page":"30","article-title":"Meropenem for management of valproic acid overdose: a case report","volume":"35","author":"Mu\u00f1oz-Pichuante","year":"2020","journal-title":"Drug Metab Pers Ther."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"690.e2","DOI":"10.1016\/j.ajem.2019.09.011","article-title":"Meropenem as an antidote for intentional valproic acid overdose","volume":"38","author":"Thomas","year":"2020","journal-title":"Am J Emerg Med."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1017\/ice.2019.50","article-title":"Outcomes from an inpatient beta-lactam allergy guideline across a large US health system","volume":"40","author":"Blumenthal","year":"2019","journal-title":"Infect Control Hosp Epidemiol."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/00002018-199615020-00001","article-title":"Neurotoxicity of carbapenem antibacterials","volume":"15","author":"Norrby","year":"1996","journal-title":"Drug Saf."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000973","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:15:19Z","timestamp":1748970919000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000973","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"2021-06-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}